26 de abril de 2017 / 12:18 / en 8 meses

BRIEF-FDA clears Flex Pharma's FLX-787 to commence US phase 2 trial in ALS under IND

April 26 (Reuters) - Flex Pharma Inc:

* FDA clears Flex Pharma’s FLX-787 to commence us phase 2 trial in ALS under ind

* FDA clears flex Pharma’s FLX-787 to commence us phase 2 trial in ALS under IND

* Flex Pharma Inc - expects to begin enrolling us patients this summer in this randomized, controlled, double-blinded, parallel design study

* Flex Pharma Inc - in addition, company has exploratory phase 2 studies currently ongoing in patients with ms and ALS in Australia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below